Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-cash Items (2016 - 2025)

Ironwood Pharmaceuticals' Non-cash Items history spans 16 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Non-cash Items fell 25.13% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $3.4 million, down 25.13%, while the annual FY2025 figure was $3.4 million, 25.13% down from the prior year.
  • Non-cash Items for Q4 2025 was $3.4 million at Ironwood Pharmaceuticals, down from $4.5 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $5.8 million in Q4 2022 and bottomed at $2.9 million in Q4 2023.
  • The 5-year median for Non-cash Items is $4.5 million (2021), against an average of $4.2 million.
  • The largest annual shift saw Non-cash Items tumbled 49.53% in 2023 before it skyrocketed 55.49% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $4.5 million in 2021, then rose by 27.78% to $5.8 million in 2022, then tumbled by 49.53% to $2.9 million in 2023, then surged by 55.49% to $4.5 million in 2024, then fell by 25.13% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Non-cash Items are $3.4 million (Q4 2025), $4.5 million (Q4 2024), and $2.9 million (Q4 2023).